Accelerated Approvals Need Earlier Planning On Surrogate Endpoints, Postmarketing Trials – FDA’s Marks

 
• By Sue Sutter
  
Off-ramp
Accelerated approval sometimes has been 'like an off-ramp for problems' with an application, FDA's Peter Marks said. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies